Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
ESMO Open
|
February 8, 2021
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma<sup>☆</sup>
A A Tarhini, K Toor, K Chan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 29, 2019
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response
J E Stein, A Soni, L Danilova, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 14, 2017
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
Tara C Gangadhar, Wen-Jen Hwu, Michael A Postow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 7, 2014
PD-L1 expression in nonclear-cell renal cell carcinoma
T K Choueiri, A P Fay, K P Gray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 2019
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O Hamid, C Robert, A Daud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial
J Guo, R D Carvajal, R Dummer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
A J Schoenfeld, S J Antonia, M M Awad, et al.
Cancer Journal (Sudbury, Mass.)
|
July 6, 2000
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
E Jonasch, U N Kumar, G P Linette, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2024
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
C Robert, G V Long, J Larkin, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 28, 1998
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
R Soiffer, T Lynch, M Mihm, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
ESMO Open
|
February 8, 2021
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma<sup>☆</sup>
A A Tarhini, K Toor, K Chan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 29, 2019
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response
J E Stein, A Soni, L Danilova, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 14, 2017
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
Tara C Gangadhar, Wen-Jen Hwu, Michael A Postow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 7, 2014
PD-L1 expression in nonclear-cell renal cell carcinoma
T K Choueiri, A P Fay, K P Gray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 2019
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O Hamid, C Robert, A Daud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial
J Guo, R D Carvajal, R Dummer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
A J Schoenfeld, S J Antonia, M M Awad, et al.
Cancer Journal (Sudbury, Mass.)
|
July 6, 2000
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
E Jonasch, U N Kumar, G P Linette, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2024
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
C Robert, G V Long, J Larkin, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 28, 1998
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
R Soiffer, T Lynch, M Mihm, et al.
Page
of 2